Advertisement
Canada markets open in 6 hours 50 minutes

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7310
    +0.0012 (+0.17%)
     

  • CRUDE OIL

    82.94
    +0.13 (+0.16%)
     

  • Bitcoin CAD

    87,997.53
    -3,286.73 (-3.60%)
     

  • CMC Crypto 200

    1,390.87
    +8.30 (+0.60%)
     

  • GOLD FUTURES

    2,331.10
    -7.30 (-0.31%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,418.75
    -245.75 (-1.39%)
     

  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6813
    -0.0006 (-0.09%)
     

Stocks in play: PharmaTher Holdings Ltd.

Baystreet.ca
·1 min read

Announced that the U.S. Food and Drug Administration has approved the Company’s Investigational New Drug application to proceed with a Phase 2 clinical trial to evaluate the safety, efficacy and pharmacokinetics of ketamine in the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease. PharmaTher expects to begin enrolling patients in the Phase 2 clinical trial in Q3-2021. Assuming the Phase 2 clinical trial is positive, the Company will request a meeting with the FDA to discuss its plan and obtain an agreement to move to a Phase 3 clinical study under the 505(b)(2) regulatory pathway next year. PharmaTher Holdings Ltd. shares C.PHRM are trading unchanged at $0.19.

Read: